The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 26, 2019

Filed:

Nov. 09, 2015
Applicant:

Rheinische Friedrich-wilhelms-universität Bonn, Bonn, DE;

Inventors:

Gunther Hartmann, Bonn, DE;

Veit Hornung, Pullach, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 31/7115 (2006.01); A61K 31/7105 (2006.01); C07H 21/00 (2006.01); A61K 45/06 (2006.01); C12N 15/117 (2010.01);
U.S. Cl.
CPC ...
A61K 31/7115 (2013.01); A61K 31/7105 (2013.01); A61K 45/06 (2013.01); C07H 21/00 (2013.01); C12N 15/117 (2013.01); C12N 2310/17 (2013.01); C12N 2310/31 (2013.01); C12N 2310/32 (2013.01); C12N 2310/335 (2013.01); C12N 2310/346 (2013.01); C12N 2310/351 (2013.01); C12N 2320/30 (2013.01);
Abstract

Oligonucleotides bearing free, uncapped 5' phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1β production. Bacterial RNA also induces type I IFN production. 5′ phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1β production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5′ triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1β production, in a target cell-specific manner.


Find Patent Forward Citations

Loading…